Worthy Technology" is committed to building an AI pharmaceutical industry platform
Worthy Technology, which aims to build an AI decision-making platform for pharmaceutical industry scenarios, has recently announced the completion of a 10 million yuan angel round of financing, with the investor being linear capital, and the previous round of shareholders continuing to make additional investments.
WoTech said, the next step is to build AI automated synthesis platform, combined with the use of hardware integration and software fine control, to achieve breakthroughs in the field of synthesis automation, and then empower R & D personnel to play an advantage in a more creative field. We are already in talks with customers and expect to launch a prototype next year.
Deep Genomics completes $180M in Series C funding
Recently, AI-driven RNA therapeutics development company Deep Genomics announced the completion of a $180M Series C funding round. The funds received will be used to advance the Deep Genomics AI platform and the development of its RNA therapeutics pipeline.
Deep Genomics has built a system called AI Workbench, which has made billions of predictions about the entire human genome, millions of genetic variants, and hundreds of millions of new compounds. AI Workbench has now been iterated to version 3.0 to support target identification and drug discovery for more common and complex diseases, with disease areas spanning neurodevelopmental, neurodegenerative, and metabolic disorders.
'T-knife': Bringing TCR-T cell therapies to the clinic
Recently, T-knife Therapeutics, an over-the-counter T-cell therapy company, raised a $110 million Series B funding round for the development of next-generation, fully personalized de novo antigenic T-cell receptor (TCR) therapies.
Through the pioneering work of its founder, Professor Thomas Blankenstein, T-knife has established its proprietary HuTCR transgenic mouse platform that carries the entire human TCR αβ locus and expresses only human TCRs restricted to human HLA, while studies have also demonstrated the ability to immunize HuTCR mice against human tumor antigens. HuTCR mice identifies CD4+ and CD8+ T cells with optimized affinity/specificity profiles of TCRs, and is able to significantly enhance the anti-tumor activity of the cells. t-knife has established a very diverse library of TCRs through effective gene initiation and TCR selection in subsequent work. This natural high-affinity TCR selection platform was also utilized to develop a series of unique patented TCR drug candidates for clinical development.
"Zhonghui Yuantong" secured over 600 million RMB in Pre-IPO round financing
Zhonghui Yuantong secured over 600 million RMB in Pre-IPO round financing, with investors such as Pacific Century Capital, HongHui Capital, Guohai Creative Capital, and Pine Harvest Capital.
Zhonghui Yuantong is a professional company engaged in vaccine research and development, registration and declaration, industrialization and sales. Currently, the company has obtained four Class I new drug clinical approvals for pediatric quadrivalent influenza virus subunit vaccine, adult quadrivalent influenza virus subunit vaccine, recombinant herpes zoster vaccine, and nine-valent recombinant human papillomavirus vaccine, and one Class IX new drug clinical approval for 23-valent pneumococcal polysaccharide vaccine.
Kindik Bio" was listed on the Science and Technology Board of the Shanghai Stock Exchange
On August 2, Kindik Bio was officially listed on the Science and Technology Board of the Shanghai Stock Exchange. According to the prospectus of Jindicic Bio, the company's sponsor for this IPO is CITIC Securities, and the issue price is RMB 55.18/share, raising a total of about RMB 1.6 billion. Founded in 2008, Jindike Bio has been specializing in the research, development, production, and sales of human vaccines.
"BMD" Focuses on Vascular Intervention
BMD Medical Imaging Technology (Shanghai) Co., Ltd. announced the completion of its US$100 million Series C financing. The funding will be used to accelerate the commercialization of the company's products, develop new products and clinical registrations, and further improve the global layout of vascular interventional diagnostics.
Founded in September 2015 in Shanghai by a senior management team and top scientists from around the world, BMD is committed to becoming a global leader in vascular interventional diagnostics. The company's products cover the complete vascular interventional diagnostic and treatment industry chain, including precise screening of vascular diseases, intraoperative diagnosis and surgical planning, postoperative efficacy assessment and patient risk prediction. Up to now, BMD owns more than 70 patents from China, the US, Germany, Japan and other countries, and has many of the world's first and foremost technologies.
"Enzymotec" exosome + medical services
Recently, Beijing Enzymotec Bio-technology Company Limited (Enzymotec) announced the completion of nearly 100 million yuan of Series A financing. The proceeds of the financing will be mainly used for the construction of the company's exosome therapeutic pilot plant, preclinical series of products research and development, as well as exosome engineering and transformation of technology platform.
Enzymotec was founded in 2017, the company is the first domestic commitment to exosome technology development and clinical transformation of innovative high-tech enterprises, its business segments are mainly divided into: one, is based on the exosome of the innovative drug research and development, mainly covering the tumor immunity, rare diseases and neurological disorders and other fields; two, exosome-based translational medicine research services, mainly with clinical experts Second, exosome-based translational medicine research services, mainly with clinical experts to carry out scientific research, the current business has covered the country's major cities, and has established cooperation with more than 50 well-known domestic tertiary hospitals and research institutions and a number of precision medicine enterprises.
Neukio Biotherapeutics develops new technology platforms and products for NK
Recently, Neukio Biotherapeutics announced that it has completed a $40 million angel round of financing. The funding will be used primarily for the construction of a research and development facility and the early development of generic off-the-shelf immune cell technology platforms and products.
Dr. Liqun Wang, Founder, Chairman and CEO of StarEon, has extensive technical expertise and R&D management experience in the biopharmaceutical field in the US and China, and was the founding President of Fosun Kite, a joint venture between Fosun Pharmaceuticals and Kite USA. Dr. Liqun Wang said, "StarEon is starting again from Shanghai FTZ One Life Science Park and is building a core team that is confident to make 0 to 1 innovation in the field of universal cell therapy. The company's angel round of financing has been favored by a number of renowned innovative drug investment institutions, and we are very grateful to Lilly Asia Fund, IDG Capital and Sherpa Investments for their recognition and support of our core team's capabilities and technological innovation concepts."
DaOak, the leader in organoid chips
DaOak recently announced that it has received tens of millions of dollars in Series A+ financing. The company is known as a pioneer in the field of Organoid-on-a-Chip (OOC) in China. CEO Zhou Yu revealed that the financing, in addition to accelerating the layout of the organoid chip industry chain, will focus on advancing the iteration of the organoid chip technology, providing high bionic and high throughput models for innovative drug development in the fields of cancer, neurodegenerative diseases, inflammatory diseases, etc., and improving the standardized cultivation system of organoid chips as well as the quality of the products and services they provide. We will also improve the standardized culture system of organoid and its application in the field of personalized precision medicine.
"Ring" Focuses on Gene Therapy
Recently, Ring Therapeutics closed a $117 million Series B financing round, and will next address the challenges of gene therapy head-on by introducing a new gene therapy vector platform.
Ring utilized the ****born viral set to create Anellovectors, engineered vectors consisting of single-stranded DNA rings that, once used, are retained in the nucleus of the cell as an add-on. These engineered finger ring viral vectors are able to transfer DNA into new cells without damaging healthy tissue or activating the patient's immune system. Therefore, if a patient with an immune disorder or relapse needs to be re-administered, the patient is fully capable of repeat administration without the pitfalls of a single dose.
Since its founding in 2017, Ring has been working on researching which viruses do not cause disease in order to determine which viruses are present in and between humans. The company has identified thousands of candidate vectors based on fingerling viruses and has the potential to enable gene therapies and nucleic acid drugs in a variety of diseases. The $117 million Series B financing will help Ring expand its vector platform, continue to build its manufacturing capabilities to produce libraries of vectors for preclinical testing, and fund a study to get the company into the clinic as quickly as possible.